Their next target is to use this technology in CAR T-cell immunotherapy, which reprograms the immune system to hunt and destroy cancer cells.
A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even years after treatment.
University of South Australia scientists have developed a powerful new way to uncover the genetic interactions that fuel cancer progression, paving the way for earlier and more precise treatments.
A new study reveals that a rarely-diagnosed and frequently drug-resistant species, Aspergillus tubingensis, may be one of the most common causes of fungal infections in Southern California.
A genetic variant is likely putting some children suffering with myocarditis—inflammation of the heart muscle—at higher risk of developing heart failure, which can be fatal, according to a study published in Circulation Heart Failure.
A Northwestern Medicine study published in the Journal of Clinical Investigation has uncovered a connection between a well-known cancer-related protein and a major RNA modification process, which may inform new treatment strategies against prostate cancer.
The test, which runs on the cobas liat system, is said to deliver results in 15 minutes.
Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible for more than 900,000 deaths in 2020.
Cedars-Sinai scientists have developed an experimental drug that repairs DNA and serves as a prototype for a new class of medications that fix tissue damage caused by heart attack, inflammatory disease or other conditions.
A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumors such as triple-negative breast cancer has been developed by researchers.